Begin main content


We found 6820 result(s)

Denosumab (Drug Plan Submission) (Xgeva)

Last Updated: September 7, 2018
Result type: Reports
Product Line: Common Drug Review
Generic Name: Denosumab (Drug Plan Submission)
Indications: Prevention of skeletal-related events due to bone metastases from breast cancer

  • Brand Name: Xgeva
  • Manufacturer: Amgen Canada Inc.
  • Project Number: SR0433-000
  • Project Status: Complete
  • Submission Type: New

Supply Management Application to Rank Uses of Technetium-99m (The “S.M.A.R.T.” Tool) Reports

Last Updated: April 29, 2015
Result type: Resources

CADTH’s study on medical isotopes includes a number of reports to support the health care system in optimizing the use of medical isotopes and alternatives. Reports Summary Reports Project in Brief Summary for Radiologists Final Reports Optimizing Health System Use of Medical Isotopes and Other Imaging Modalities (with Appendices) ...

Frequently Asked Questions: Expanding the CADTH Drug Review Process to Receive Patient Input Submissions From Individual Patients and Caregivers

Published on: October 5, 2015
Result type: General Content

Who is eligible under the newly expanded process to submit patient input to the CADTH pan-Canadian Oncology Drug Review (pCODR) program as an individual patient or caregiver? pCODR will accept patient input from individual patients and caregivers when there is no patient advocacy group representing patients with the particular tumour for w...

Dr. Luc Boileau

Published on: January 14, 2011
Result type: General Content

Member — Observer (Quebec) As a doctor trained at the Université de Sherbrooke and a specialist in public health, Dr. Luc Boileau holds a master’s in health administration from the Université de Montréal and a fellowship from the Canadian Health Services Research Foundation. In addition to his 25 years of clinical experience — particularly in...